Clinical and Dopamine Transporter Imaging Characteristics of Leucine‐ Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study

Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease

(2019) Tal Kozlovski et al.   Frontiers in Neurology

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

(2019) Tanya Simuni et al.   LANCET NEUROLOGY

GBA-Associated Parkinson’s Disease and Other Synucleinopathies

(2018) Ziv Gan-Or et al.   Current Neurology and Neuroscience Reports

Features ofGBA-associated Parkinson’s disease at presentation in the UKTracking Parkinson’sstudy

(2018) Naveed Malek et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls

(2018) Steven A. Gunzler et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Progression in the LRRK2-Associated Parkinson Disease Population

(2018) Rachel Saunders-Pullman et al.   JAMA Neurology

Movement disorder society criteria for clinically established early Parkinson's disease

(2018) Daniela Berg et al.   MOVEMENT DISORDERS

Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease

(2018) Shu-Ying Liu et al.   PARKINSONISM & RELATED DISORDERS

New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics

(2018) S. Pablo Sardi et al.   PARKINSONISM & RELATED DISORDERS

Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations

(2018) Gilad Yahalom et al.   PARKINSONISM & RELATED DISORDERS

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

(2018) Kenneth Marek et al.   Annals of Clinical and Translational Neurology

Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature

(2017) E. S. Fagan et al.   EUROPEAN JOURNAL OF NEUROLOGY

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies

(2017) Daryl J Wile et al.   LANCET NEUROLOGY

Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles

(2017) Stefanie Lerche et al.   MOVEMENT DISORDERS

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's

(2016) Ganqiang Liu et al.   ANNALS OF NEUROLOGY

Survival and dementia inGBA-associated Parkinson's disease: The mutation matters

(2016) Roberto Cilia et al.   ANNALS OF NEUROLOGY

Neuropsychiatric characteristics of GBA-associated Parkinson disease

(2016) Matthew Swan et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Impulsive-compulsive behaviors inparkin-associated Parkinson disease

(2016) Francesca Morgante et al.   NEUROLOGY

High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews

(2016) Tamara Shiner et al.   JAMA Neurology

GBAVariants are associated with a distinct pattern of cognitive deficits in Parkinson's disease

(2015) Ignacio F. Mata et al.   MOVEMENT DISORDERS

Cognitive profile ofLRRK2-related Parkinson's disease

(2015) Sindhu Srivatsal et al.   MOVEMENT DISORDERS

Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene

(2015) Johanne Hatteland Somme et al.   PARKINSONISM & RELATED DISORDERS

LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis

(2015) Ziv Gan-Or et al.   PARKINSONISM & RELATED DISORDERS

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease

(2015) Roy N. Alcalay et al.   PARKINSONISM & RELATED DISORDERS

Evolution of Prodromal Clinical Markers of Parkinson Disease in aGBAMutation–Positive Cohort

(2015) Michelle Beavan et al.   JAMA Neurology

Novel recruitment strategy to enrich forLRRK2mutation carriers

(2015) Tatiana Foroud et al.   Molecular Genetics & Genomic Medicine

GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study

(2014) Kathrin Brockmann et al.   MOVEMENT DISORDERS

Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction

(2013) Edward I. Ginns et al.   MOLECULAR GENETICS AND METABOLISM

Parkinson disease phenotype in Ashkenazi jews with and withoutLRRK2G2019S mutations

(2013) Roy N. Alcalay et al.   MOVEMENT DISORDERS

Genetics of Parkinson's disease – state of the art, 2013

(2013) Vincenzo Bonifati   PARKINSONISM & RELATED DISORDERS

Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs WithoutGBAMutations

(2013) Lama M. Chahine et al.   JAMA Neurology

GBA-associated PD presents with nonmotor characteristics

(2011) K. Brockmann et al.   NEUROLOGY

Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease

(2011) Samia Ben Sassi et al.   PARKINSONISM & RELATED DISORDERS

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

Frequency of Known Mutations in Early-Onset Parkinson Disease

(2010) Roy N. Alcalay et al.   ARCHIVES OF NEUROLOGY

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

LRRK2 G2019S mutation in Parkinson’s disease: A neuropsychological and neuropsychiatric study in a large Algerian cohort

(2010) Soreya Belarbi et al.   PARKINSONISM & RELATED DISORDERS

LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease

(2009) Z. Gan-Or et al.   NEUROGENETICS

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

(2008) Daniel G Healy et al.   LANCET NEUROLOGY